No Data
No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Xiangxue PharmaceuticalLtd (SZSE:300147) Is Carrying A Fair Bit Of Debt
Xiangxue Pharmaceutical (300147.SZ) has been applied for pre-reconstruction by creditor Jinglong Construction.
Xiangxue Pharmaceutical (300147.SZ) announced that the company recently received a notice from the creditor Guangdong Jinglong Construction Group Co., Ltd. (simplified...
Xiangxue Pharmaceutical (300147.SZ): A projected loss of 0.5996 billion yuan to -0.8624 billion yuan for the year 2024.
On January 15, Gu Longhui reported that Xiangxue Pharmaceutical (300147.SZ) announced its performance forecast for 2024. The net income attributable to shareholders of the listed company is expected to be a loss of 0.5996 billion to 0.8624 billion yuan, compared to a loss of 388.96 million yuan in the same period last year. The net income after deducting non-recurring gains and losses is expected to be a loss of 0.571 billion to 0.834 billion yuan, compared to a loss of 344.46 million yuan in the same period last year. The revenue is expected to be 1.613 billion to 2.013 billion yuan, while the revenue after deductions is expected to be 1.586 billion to 1.986 billion yuan. In 2024, the company will focus on its development strategy and annual operational goals through
Xiangxue Pharmaceuticals: 2024 Annual Results Forecast
More Unpleasant Surprises Could Be In Store For Xiangxue Pharmaceutical Co.,Ltd.'s (SZSE:300147) Shares After Tumbling 28%
Xiangxue Pharmaceutical Co.,Ltd.'s (SZSE:300147) 29% Dip In Price Shows Sentiment Is Matching Revenues
